Novartis-backed Homology Medicines priced its shares at $16 and raised $165m when it floated on the Nasdaq Global Select Market.
Homology Medicines, a US-based rare disease treatment developer backed by pharmaceutical firm Novartis, has raised $165.6m in its initial public offering and listed on the Nasdaq Global Select Market.
The company, which had originally targeted $100m in proceeds, priced its shares at $16 each, offering a total of nine million shares to investors. The shares were trading at $16.49 at close yesterday, giving Homology a market cap of approximately $627.9m.
Founded in 2015, Homology Medicines is working on gene…
